NASDAQ:IRWD - Ironwood Pharmaceuticals Price Target & Analyst Ratings Sign in or create an account to add this stock to your watchlist. Get Started $11.26 +1.36 (+13.74 %) (As of 05/19/2019 04:00 PM ET)Previous Close$11.26Today's Range$9.84 - $11.4552-Week Range$9.07 - $21.20Volume5.66 million shsAverage Volume1.48 million shsMarket Capitalization$1.74 billionP/E RatioN/ADividend YieldN/ABeta1.89 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Analyst Ratings Ironwood Pharmaceuticals (NASDAQ:IRWD) Price Target and Consensus Rating (How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.11 Wall Street analysts have issued ratings and price targets for Ironwood Pharmaceuticals in the last 12 months. Their average twelve-month price target is $15.3889, suggesting that the stock has a possible upside of 36.67%. The high price target for IRWD is $20.00 and the low price target for IRWD is $11.00. There are currently 7 hold ratings and 4 buy ratings for the stock, resulting in a consensus rating of "Hold."Today30 Days Ago90 Days Ago180 Days AgoConsensus Rating: HoldHoldHoldHoldConsensus Rating Score: 2.362.312.252.00Ratings Breakdown: 0 Sell Rating(s)7 Hold Rating(s)4 Buy Rating(s)0 Strong Buy Rating(s)1 Sell Rating(s)7 Hold Rating(s)5 Buy Rating(s)0 Strong Buy Rating(s)2 Sell Rating(s)5 Hold Rating(s)5 Buy Rating(s)0 Strong Buy Rating(s)4 Sell Rating(s)4 Hold Rating(s)4 Buy Rating(s)0 Strong Buy Rating(s)Consensus Price Target: $15.3889$17.35$17.50$16.45Price Target Upside: 36.67% upside30.55% upside18.64% upside36.74% upsideIronwood Pharmaceuticals (NASDAQ:IRWD) Consensus Price Target History Ironwood Pharmaceuticals (NASDAQ:IRWD) Analyst Ratings History Show: Only the Most Recent Rating From Each Brokerage All Ratings For This Stock DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails5/6/2019WedbushReiterated RatingNeutral$14.00 ➝ $11.00Low5/3/2019Morgan StanleySet Price TargetHold$13.00Low5/2/2019MizuhoSet Price TargetBuy$20.00High3/22/2019Credit Suisse GroupSet Price TargetHold$16.00Low2/26/2019Wood & CompanyInitiated CoverageBuyMedium2/25/2019GMP SecuritiesUpgradeSell ➝ Neutral$11.50 ➝ $14.00High2/25/2019HC WainwrightUpgradeSell ➝ Neutral$11.50 ➝ $14.00Low2/14/2019BTIG ResearchSet Price TargetBuy$19.00High1/24/2019JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral$11.00 ➝ $13.00Low11/1/2018Wells Fargo & CoLower Price TargetOutperform$18.50Low7/18/2018CowenReiterated RatingOutperform ➝ Market PerformHigh5/2/2018BarclaysBoost Price TargetEqual Weight ➝ Equal Weight$16.00 ➝ $20.00Low4/19/2018Berenberg BankInitiated CoverageBuy$25.00Medium1/5/2018Bank of AmericaDowngradeBuy ➝ Underperform$20.00 ➝ $15.00High(Data available from 5/19/2017 forward) This page was last updated on 5/19/2019 by MarketBeat.com StaffFeatured Article: How to calculate the annual rate of depreciation Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.